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AbstrACt
Introduction Lung cancer is the most common neoplasm 
and the leading cause of cancer-related death worldwide. 
Non-small cell lung cancer (NSCLC), accounting for 85% 
of all lung cancer cases, is frequently diagnosed at an 
advanced and metastatic stage. In addition, survival of 
patients with NSCLC has not improved significantly over 
the recent decades. Statins are used as a cholesterol-
lowering agent, but recently preclinical and clinical 
studies have revealed their anticancer effects. Thus, 
this systematic review and meta-analysis aims to clarify 
whether statins improve the prognosis of patients with 
NSCLC.
Methods and analysis We will search MEDLINE 
(PubMed), EMBASE, Web of Science, the Cochrane Central 
Register of Controlled Trials and  ClinicalTrials. gov with 
no restriction on language. Both randomised controlled 
trials (RCTs) and observational cohort studies evaluating 
the prognostic role of statins in patients with NSCLC will 
be included. The primary outcome will be overall survival, 
and the secondary outcomes will include cancer-specific 
survival, disease-free survival and cancer recurrence. 
Two assessors will assess the RCTs using the Cochrane 
Collaboration’s risk of bias tool and the observational 
cohort studies according to ROBINS-I. Publication bias 
will be assessed by funnel plot using the STATA software 
v.13.1.
Ethics and dissemination No ethical issues are 
predicted. This systematic review and meta-analysis aims 
to describe the prognostic effects of statins in patients 
with NSCLC, which would help clinicians to optimise 
treatment for patients with NSCLC. These findings will be 
published in a peer-reviewed journal and presented at 
national and international conferences.
PrOsPErO registration number CRD42016047524.
IntrOduCtIOn 
Lung cancer is the most common malignant 
tumour and the leading cause of cancer-re-
lated death all over the world.1 The incidence 
rate of lung cancer still shows an alarming 
trend.2 Clinically, small cell lung cancer and 
non-small cell lung cancer (NSCLC) are 
two main subtypes of lung cancer, of which 
NSCLC accounts for approximately 85% of 
the cases.1 3 4 In recent years, although studies 
have shown survival benefits from low-dose 
CT screening and tyrosine kinase inhibi-
tors (TKI) specific for epidermal growth 
factor receptor (EGFR),5–11 the 5-year lung 
cancer-specific survival is only 18%.1 This is 
partly because most patients are diagnosed 
at an advanced stage of the disease, and a 
large proportion of patients with advanced 
NSCLC are resistant to radiotherapy and 
chemotherapy, as well as targeted therapy.1 4 
Therefore, there is an urgent requirement to 
explore new therapies and optimise current 
treatment to improve the survival of patients 
with NSCLC.
Statins are inhibitors of 3-hydroxy 3-meth-
ylglutaryl-CoA (HMG-CoA) reductase, which 
is the rate-controlling enzyme in the produc-
tion of mevalonate.12 Statins can reduce the 
plasma cholesterol level, and are the most 
commonly used drugs for preventing cardio-
vascular diseases and decreasing mortality 
and morbidity.13 14 Mounting evidence has 
demonstrated that statins are involved in the 
function of EGFR-related signalling path-
ways and c-Jun N-terminal kinase pathway.15 
Furthermore, previous studies have indi-
cated that statins exert anticancer effects by 
strengths and limitations of this study
 ► This is the first systematic review aiming to sum-
marise the evidence on whether statins improve the 
prognosis of patients with non-small cell lung can-
cer (NSCLC).
 ► Another strength could be the inclusion of both ran-
domised studies and observational studies.
 ► This systematic review will be limited to excluding 
unpublished studies and including studies with the 
timing of intervention being both before and after 
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inducing apoptosis and inhibiting tumour cell growth 
and angiogenesis.16–18 Although it is controversial, many 
previous clinical publications suggest that statin use is asso-
ciated with improved survival in patients with NSCLC.19–21 
This systematic review and meta-analysis will explore the 
effects of statins in patients with NSCLC.
ObjECtIvEs
This systematic review and meta-analysis aims to 
summarise the existing evidence to determine whether 
statins change the prognosis of patients with NSCLC. 
The primary objective is to demonstrate whether statins 
improve the overall survival of patients with NSCLC. The 
secondary objectives are to assess whether cancer recur-
rence, cancer-specific survival and disease-free survival 
differ between statins-using and non-statins-using patients 
with NSCLC.
MEthOds
This systematic review has been developed in accor-
dance with the guidelines detailed on the Preferred 
Reporting Items for Systematic Reviews and Meta-Anal-
yses (PRISMA) checklist,22 and the protocol is reported 
according to its extension for protocols (PRISMA-P 
2015).23 24 In addition, the flow chart (figure 1) will be 
employed in describing the study identification and selec-
tion process. The protocol of this systematic review has 




We will include both randomised controlled trials (RCTs) 
and observational cohort studies. Studies assessing cell 
lines and animal models only, review articles, proceedings, 
conferences and case–control studies will be excluded.
type of participants
We will include all patients of both genders who are diag-
nosed with NSCLC. Tumour classification will be made 
according to the 2011 WHO classification.25
type of intervention
The intervention will be use of statins, which means 
patients who have taken statins at any type or dose before 
or after the diagnosis will be included in the treatment 
group.
type of control
The control group will be patients who have been allo-
cated to the control group during the study, which means 
Figure 1 Flow chart showing identification and screening of eligible studies from MEDLINE, EMBASE, Cochrane Central 








pen: first published as 10.1136/bmjopen-2018-022161 on 10 September 2018. Downloaded from 
3Li F, et al. BMJ Open 2018;8:e022161. doi:10.1136/bmjopen-2018-022161
Open access
the comparators given can be either placebos or no treat-
ment of statins.
type of outcomes
The primary outcome will be overall survival of patients 
with NSCLC. The secondary outcomes will include 
cancer recurrence, cancer-specific survival and disease-
free survival.
sEArCh strAtEgy
We will search the following databases: MEDLINE 
(PubMed), EMBASE, Web of Science, the Cochrane 
Central Register of Controlled Trials and the  Clinical-
Trials. gov, until 31 July 2018.
PubMed search strategy
The details of the PubMed database search strategy and 
syntax are sequentially provided in online supplementary 
appendix 1.
Other resources
The reference lists of the relevant original studies will 
be searched for additional studies, as well as reviews and 
key journals, such as ‘Lung Cancer’ (until 31 July 2018), 
‘Clinical Lung Cancer’ (until 31 July 2018), ‘Clinical Cancer 
Research’ (until 31 July 2018), ‘Journal of Clinical Oncology’ 
(until 31 July 2018), ‘JAMA’ (until 31 July 2018), ‘Lancet’ 
(until 31 July 2018) and ‘the New England Journal of Medi-
cine’ (until 31 July 2018). The hand-searching approach 
will be a manual page-by-page examination of all the 
issues.
There will be no restrictions on language or publica-
tion year. Studies written in languages other than English 
will be translated with the help of international scientists 
in our institutes. In addition, we will exclude unpublished 
studies.
data collection and analysis
Selection of studies
Two reviewers will independently screen the titles and 
abstracts of all studies identified from the databases 
according to the inclusion criteria. Subsequently, the 
full texts of the identified studies will be reassessed inde-
pendently by the two reviewers, verifying the reasons for 
inclusion and exclusion. Disagreements will be resolved 
by consulting a third reviewer.
Data extraction
A data extraction form will be developed, and the study 
data will be independently assessed and extracted by two 
reviewers. The following data will be extracted from all 
the included studies:
1. Study characteristics (author, year of publication, study 
design, setting, locations and patient enrolment strate-
gies, and sample size).
2. Participants’ characteristics (age, gender, ethnicity, 
smoking status, alcohol consumption, histopathologi-
cal diagnosis, tumour, node, metastases (TNM) stage, 
history of treatment, associated comorbidities, timing 
of administration of statins, type of statins, dose of 
statins, comparator given and follow-up period).
If the reported data are not sufficient, we will contact 
the authors for further information. We will also pay extra 
attention to the confounding factors in the retrospective 
observational cohort studies.
Assessment of methodological quality
Two assessors will assess the methodological quality of 
RCTs using the Cochrane Collaboration’s risk of bias 
tool26 and observational studies according to The Risk 
Of Bias In Non-randomized Studies – of Interventions 
(ROBINS-I).27 ROBINS-I is a new tool to assess risk of bias 
in non-randomised studies of interventions. ROBINS-I has 
seven domains of bias, including bias due to confounding, 
selection of participants, interventions themselves, devia-
tions from intended interventions, missing data, measure-
ment of outcomes and selection of the reported result. 
We have identified the following confounders: TNM stage 
and history of treatment (including chemotherapy, radio-
therapy, targeted therapy and surgical therapy), which are 
important for the survival of patients with NSCLC. The 
reviewers should respond to the questions on signalling 
to judge the risk of bias in each domain, finally acquiring 
an overall risk of bias judgement for the outcome being 
assessed. Disagreements will be resolved by consulting a 
third independent reviewer.
Measures of treatment effect
The HR will be used to summarise survival data and dichot-
omous data, respectively, along with 95% CI. If an HR is 
not presented in an eligible study, for example only an OR 
or relative risk (RR) is available, we will estimate the HR 
using the information available in the study according to 
the methods reported in the previous studies.28 29 Because 
if there are sufficient data to estimate an OR or RR, then 
there are usually sufficient data to estimate an HR. Also, if 
multiple effect estimates are presented in a paper, we will 
extract the result adjusted for the greatest number of our 
prespecified confounders.30
Addressing missing data
Missing relevant data will be excluded from analysis only 
after contacting the author but failing to acquire them. 
Sensitivity analysis will be conducted to explore if these 
missing data will influence the results of the meta-analysis.
Assessment of heterogeneity
Heterogeneity among studies will be measured using 
the Cochran Q test (χ2) and I2 test. We will interpret it 
using the following guide: I2, 0%–25% suggesting low 
heterogeneity, 25%–50% moderate heterogeneity and 
75%–100% high heterogeneity.
Assessment of reporting bias
Since detecting and overcoming publication bias are 
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use funnel plot to assess reporting bias, with results being 
interpreted cautiously.
Strategy for data synthesis
Extracted data will be entered into Review Manager V.5.3 
software for aggregating risk estimates (HR and 95% CI) 
by the first researcher and independently checked by the 
second one. We will use fixed-effect or random-effects 
methods as appropriate for analysis. If heterogeneity 
among the studies is identified as considerable, we will 
apply the random-effects method for analysis.
Subgroup analyses
Subgroup analyses are planned as follows:
1. Associated comorbidity such as hyperlipidaemia, coro-
nary heart disease and so on.
2. Disease stage.
3. Cancer subtype.
4. Treatment type: surgery, chemotherapy and radiother-
apy.
5. The time points at which patients start to take statins: 
prediagnosis or postdiagnosis.
6. Study type: RCT and retrospective studies.
7. Comparator given: placebo or no treatment.
Sensitivity analysis
A sensitivity analysis will be conducted to test the impact 
of the results with respect to the methodological quality 
items rated by the ROBINS-I and the Cochrane tool. 
Meta-analyses will be repeated after excluding studies 
with lower methodological quality and studies with 
high or unclear risk of bias. To evaluate the stability 
of the results, we will also conduct the leave-one-out 
sensitivity analysis. Sensitivity analyses will be reported 
with a summary table, and reviewed conclusions will be 
interpreted by making comparisons between the two 
meta-analyses.
Confidence in cumulative evidence
The quality of the evidence will be assessed using the 
scoring system of the Grading of Recommendations 
Assessment, Development and Evaluation Working 
Group. According to the final score, which will be 
acquired by summarising the score of each item in the 
scoring system, the quality of evidence is categorised into 
four levels: high (≥4 points), moderate (3 points), low (2 
points) and very low (≤1 point).31
Patient and public involvement
Patients and the public were not involved in this study.
dIsCussIOn
Lung cancer, especially NSCLC, is among the most 
common cancers for both men and women. Although 
many patients with NSCLC using EGFR-TKIs have 
achieved encouraging results, there are still a large 
proportion of patients who cannot benefit from them. 
Statins, considered as safe, cheap and effective drugs, 
are commonly used in the primary and secondary 
prevention of cardiovascular diseases; however, some 
preclinical and clinical studies have shed light on their 
anticancer effects and repurposed them as promising 
anticancer agents.
Our systematic review will clarify the prognostic effect of 
statins in patients with NSCLC, which would help patients 
and clinicians to optimise the treatment of NSCLC, espe-
cially patients with coexisting cardiovascular disease. This 
systematic review may also help guideline developers in 
the management of patients with NSCLC.
EthICs And dIssEMInAtIOn
No ethical issues are predicted. This systematic review and 
meta-analysis will describe the prognostic effects of statins 
in patients with NSCLC, which would help clinicians to 
optimise the treatment for patients with NSCLC. These 
findings will be published in a peer-reviewed journal and 
presented at national and international conferences.
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